Inhibition of NF-κB transcriptional activation in HepG2 cells by diterpenoids from the soft coral Sinularia maxima

Anti-inflammatory transcriptional effects of nineteen compounds (1–19) from the soft coral Sinularia maxima were evaluated using NF-κB luciferase and reverse transcriptase polymerase chain reaction. Compounds 1, 2, 4, 8, 15, 17, and 18 significantly inhibited TNFα-induced NF-κB transcriptional activity in HepG2 cells in a dose-dependent manner, with IC50 values ranging from 15.81 ± 2.29 to 29.10 ± 1.54 μM. Furthermore, the transcriptional inhibitory function of these compounds was confirmed by a decrease in intercellular adhesion molecule-1 and inducible nitric oxide synthase gene expression levels in HepG2 cells. These results provide a scientific rationale for the use of the soft coral S. maxima warrant further studies to develop new agents for the prevention and treatment of inflammatory.


Introduction
Activation of nuclear factor kappa B (NF-jB) represents a family of Rel domain-containing proteins including five NF-jB units that can form 15 transcription factors through homo-and heterodimerization (Baldwin 2001a). NF-jB plays an important role in the transcriptional regulation of numerous cytokines and adhesion molecules. It is arguably the most important transcription factor for the initiation or progression of numerous human diseases (Mattson and Camandola 2001). As a ubiquitous transcription factor governing the expression of viruses or a variety of inflammatory cytokine genes, NF-jB was first implicated in the pathogenesis of human immunodeficiency virus-1 (HIV-1) infection (Nabel and Baltimore 1987). NF-jB, a nuclear transcription factor, regulates the expression of various genes, including cytokines, iNOS, COX-2 and ICAM-1, which play critical roles in apoptosis, autoimmune diseases, and inflammation (Albert and Baldwin 1996). Further studies suggest that activation of NF-jB is responsible for the pathological progression of neurological disorders, carcinogenesis, immune deficiency, rheumatoid arthritis, atherogenesis, Crohn's disease, cystic fibrosis, asthma, osteopetrosis, ischemic reperfusion, etc. (Chen et al. 1999).

Cytotoxicity assay
A 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay (CellTiter 96 Ò AQueous One Solution Assay, Promega, Madison, WI, USA) was performed to analyze the effect of the different compounds on cell viability. Cells were cultured overnight in 96-well plates (1 9 10 4 cells per well). Cell viability was assessed after the incubation with the compounds at a concentration of 10 lM for 24 h. The number of viable cells was determined by measuring the absorbance at 490 nm of the dissolved formazan product after addition of MTS for 30 min as described by the manufacturer.

NF-jB and iNOS-luciferase assay
The luciferase vector was first transfected into HepG2 cells. After a limited amount of time, the cells were lysed and luciferin, the substrate of luciferase, was introduced into the cellular extract along with Mg 2? and an excess of ATP. Under these conditions, luciferase enzymes expressed by the reporter vector could catalyze the oxidative carboxylation of luciferin. Cells were seeded at 1.5 9 10 5 cells per well in a 12-well plate and grown for 24 h. All cells were transfected using Lipofectamine TM LTX (Invitrogen) according to the manufacturer's protocol. Luciferase (Luc) activity was assayed using an LB 953 Autolumat (EG&G Berthold, Nashua, NH, USA) as described previously (Kim et al. 2010). NF-jB-Luc was kindly provided by Dr. Kyoon E. Kim (Chungnam National University, Daejeon, Korea). The transfected HepG2 cells were pretreated for 1 h with either vehicle (DMSO) and compounds, followed by 1 h of treatment with 10 ng/mL TNFa. Unstimulated HepG2 cells were used as a negative control (-). Cells were then harvested, and luciferase activity was assayed. All experiments were performed in triplicate.

RNA preparation and RT-PCR
HepG2 cells were pretreated in the absence and presence of compounds for 1 h, then exposed to 10 ng/mL TNFa for 6 h. Total mRNA was prepared from the cell pellets using Easy-blue. The levels of mRNA were assessed by reverse transcriptase polymerase chain reaction (RT-PCR) .

Statistical analysis
All results are expressed as mean±SD values. Data were analyzed by one-factor analysis of variance. Quantification of polymerase chain reaction products was performed using Image Lab TM software (Bio-Rad). If a statistically significant effect was found, the Newman-Keuls test was performed to isolate the difference between the groups. P \ 0.5 was considered to be significant.

Results
To investigate cellular toxicity of the compounds 1-19, they were applied at various concentrations to HepG2 cells for 24 h, after which cell viability was measured in an MTS assay as described in Materials and methods. None of the compounds displayed any cellular toxicity at the concentration of 10 lM (data not shown). They were therefore used in subsequent experiments for further evaluation of their effects on NF-jB activation, iNOS and ICAM-1 expressions at concentrations of 0.1, 1.0 and 10 lM (see Fig. 4).
To evaluate the anti-inflammatory activity of nineteen compounds listed above, we first examined their inhibitory effects on NF-jB transcriptional activation in HepG2 cells (see Figs. 2, 3). Cells were treated with compounds at various concentrations prior to stimulation with TNFa (10 ng/mL). Among compounds tested, 1, 2, 4, 8, 15, 17, and 18 were found to have effect on the inhibition of NF-jB activation with 50 % inhibition concentration (IC 50 ) values ranging from 15.81 ± 2.29 to 29.10 ± 1.54 lM. Other compounds exhibited moderate, weak or not determined activities (Table 1).

Discussion
NF-jB was first described in 1986 as a nuclear transcription factor required for immunoglobulin kappa light chain transcription in B-cells. Since its discovery, it has been demonstrated that NF-jB is constitutively expressed in all cell types and plays a central role as a regulator of the cellular stress response. The NF-jB-mediated signaling pathway has been considered both pro-inflammatory and anti-apoptotic in character, and therefore, has been implicated in the pathogenesis of a wide variety of diseases, including inflammatory disorders and tumor development (Robinson and Mann 2010). As previously demonstrated, activation of NF-jB has been linked to multiple pathophysiological conditions such as cancer, arthritis, asthma, inflammatory bowel disease, and other inflammatory conditions (Baldwin 2001b). It can be activated by various stimuli, such as microbial and viral products, cytokines, DNA damage, and noxious chemicals. The induction of several pro-inflammatory mediators occurs as a result of increased inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) activities (Surha et al. 2001). NF-jB and the signaling pathways that regulate many physiological processes, including innate and adaptive immune responses, cell death, and inflammation, have become a focal point for intense drug discovery and development efforts (Chung et al. 2007;Perkins 2007). Indeed, increasing evidence has validated NF-jB as a target for anti-inflammatory and anticancer agents.
To date, the inhibition of components from S. maxima on NF-jB transcriptional activation has not been evaluated. In this study, the effects of compounds 1-19 on TNFainduced NF-jB transcriptional activity in HepG2 cells were evaluated using a NF-jB luciferase assay. To confirm their inhibitory effects of the compounds on NF-jB transcriptional activity, the effects of the isolated compounds on the upregulation of the pro-inflammatory proteins iNOS and ICAM-1 were assessed in TNFa-stimulated HepG2 cells by RT-PCR.
HepG2 cells were first transfected with NF-jB luciferase reporter plasmids. After treatment with 10 ng/mL  Table 1). NF-jB activation is known to be involved in the upregulation of inflammatory NF-jB target gene expression, including iNOS and ICAM-1, which play important roles in the inflammatory response. iNOS is highly expressed in macrophages, leading to organ destruction in some inflammatory and autoimmune diseases (Kleinert et al. 2004). ICAM-1 (CD54) is a 90-kDa inducible cellsurface glycoprotein that promotes leukocyte adhesion in inflammatory conditions (Rothlein et al. 1986;Springer 1990). Analysis of the ICAM-1 complementary deoxyribonucleic acid sequence has revealed it to be a member of the immunoglobulin gene superfamily (Staunton et al. 1988). ICAM-1 is expressed basally at low levels on many cell types, including endothelial cells, macrophages, myocytes, and vascular smooth muscle cells, but can be induced to high levels by stimulation with LPS, phorbol ester, or inflammatory cytokines, such as TNF-a or interleukin-1b (Colic and Drabek 1991;Ruetten et al. 1999).
Consideration of the structure-activity relationship of these compounds indicated that the ketone groups at C-3 and/or C-6, the hydroxyl group at C-7 and/or C-8 are necessary for the anti-inflammatory activity of diterpenoids and norditerpenoids. This finding was confirmed by comparing the structure and activity of compounds 1, 2, 4, 8, 15, 17, and 18, therefore this information may facilitate identification of anti-inflammatory lead compounds from diterpenoids and norditerpenoids. This primary finding provides support for further studies on these compounds for the development of anti-inflammatory agents.